You are here

Servier and Pfizer Obtain Rights to Cellectis Cancer Cell Therapy

Possible therapy for blood cancer is about to enter initial phase I clinical tests

U.S. drugmaker Pfizer and France's Servier have snapped up rights to a promising cell therapy developed by French biotech firm Cellectis to fight blood cancers.

The so-called CAR T-cell technology used by Cellectis involves reprogramming immune-system cells to hunt out cancer. The "off-the-shelf" approach recently proved very successful in the case of a baby whom doctors thought almost certain to die.

Cellectis said that Servier had exercised an option to acquire the exclusive worldwide rights to UCART19, which is about to enter phase I clinical tests, and Pfizer would work with Servier on the drug's development.

Pfizer will have rights to sell the treatment in the United States, with Servier responsible for marketing elsewhere. This arrangement is separate from Pfizer’s collaboration with Cellectis announced in 2014, which did not include UCART19.

Cellectis will get $38.2 million up front from Servier and is eligible for more than $300 million in milestone payments, research financing, and royalties on sales. Financial terms for the Servier agreement with Pfizer were not disclosed.

UCART19 is being tested for chronic lymphocytic leukemia and acute lymphoblastic leukemia. Cellectis is developing chimeric antigen receptor T-cell (CAR-T) immunotherapies using engineered cells from a single donor for use in multiple patients.

This so-called allogeneic approach is in contrast to other autologous technologies that rely on engineering a patient's own T-cells; the aim is to make it possible to treat cancer using a standardized off-the-shelf product. Such cells could be frozen and shipped anywhere in the world for almost immediate use.

Source: Reuters, November 19, 2015.

Recent Headlines

Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission